Skip to main content alibris logo
Antiangiogenic Cancer Therapy - Davis, Darren W. (Editor), and Herbst, Roy S. (Editor), and Abbruzzese, James L. (Editor)
Filter Results
Item Condition
Seller Rating
Other Options
Change Currency

Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities ...

loading
Antiangiogenic Cancer Therapy 2019, CRC Press, London

ISBN-13: 9780367388812

Paperback

Antiangiogenic Cancer Therapy 2007, CRC Press Inc, Bosa Roca

ISBN-13: 9780849327995

Hardcover